Hungarian Pediatric Heart Center, Gottsegen György Hungarian Institute of Cardiology, Haller u. 29, Budapest, 1096, Hungary.
Physiological Controls Research Center, Óbuda University, Budapest, Hungary.
Eur J Pediatr. 2021 Aug;180(8):2669-2676. doi: 10.1007/s00431-021-04159-z. Epub 2021 Jun 29.
Prognosis of supraventricular tachycardias in neonates and infants is thought to be excellent with rare fatal outcomes. Nevertheless, initial management can be challenging. The aim of this study was to perform a retrospective analysis in neonates/infants with non-pos-toperative supraventricular tachycardias regarding risk factors for clinical outcome and type of antiarrhythmic drug therapy. The data of 157 patients aged < 1 year who presented between 2000 and 2015 with symptomatic tachycardias were retrospectively reviewed. Pharmacological therapy was successful in 151 patients (96%); 1 patient (1%) required catheter ablation and 5 patients (3%) died (1 death linked to hemodynamical reasons after effective arrhythmia control). Serious complications following acute medical therapy occurred in 4 patients of survivors. Patients with complications or death had a lower bodyweight, more frequent intrauterine tachycardia, transplacental therapy, urgent caesarian section, higher PRISM II score, longer period to control tachycardia, more frequent proarrhythmia, and major adverse event-defined as life-threatening event without a documented new arrhythmia-compared to the group without complications. There was no significant difference between the groups regarding prematurity, structural heart disease, and type of tachycardia. Proarrhythmia occurred in 6 cases and was related to intravenous drug use with class IC antiarrhythmics in 3/6 cases, digoxin in 2/6 cases, and amiodarone in 1/6 cases. ECG signs of impending proarrhythmia without new-onset arrhythmia requiring cessation of therapy were detected in 6 patients.Conclusion: Although rare, non-post-operative supraventricular tachycardia in neonates and infants might be a serious disease. Acute intravenous pharmacological treatment to control tachycardia might pose a risk for fatal or near-fatal outcome. Detection of proarrhythmia related to class IC antiarrhythmics in neonates might be especially difficult and requires alertness. What is Known • Prognosis of supraventricular tachycardias in children are thought to be excellent with fatal outcomes being rare. • Mortality is increased in the very young and in those with structural heart disease. What is New • Complicated outcome of non-post-operative supraventricular tachycardias in neonates is associated with lower bodyweight, age, prenatal tachycardia, higher PRISM II score, longer period to control tachycardia, and proarrhythmia. • Detection of class IC proarrhythmic effect is especially difficult in neonates because of their narrow QRS and warrants alertness.
新生儿和婴儿的室上性心动过速的预后被认为是极好的,很少有致命的结果。然而,初始管理可能具有挑战性。本研究的目的是对 2000 年至 2015 年间出现非术后室上性心动过速的新生儿/婴儿进行回顾性分析,以评估其临床结果的危险因素和抗心律失常药物治疗类型。回顾性分析了 157 名年龄<1 岁的有症状心动过速患者的数据。151 名患者(96%)药物治疗成功;1 名患者(1%)需要导管消融,5 名患者(3%)死亡(1 例在有效控制心律失常后因血流动力学原因死亡)。存活患者中有 4 名在急性药物治疗后出现严重并发症。有并发症或死亡的患者体重较低,宫内心动过速更频繁,需要经胎盘治疗,紧急剖腹产,PRISM II 评分较高,控制心动过速的时间较长,更频繁的致心律失常,以及主要不良事件(无记录的新心律失常的危及生命的事件)与无并发症的患者相比。两组之间在早产、结构性心脏病和心动过速类型方面无显著差异。致心律失常发生在 6 例,与静脉内使用 IC 类抗心律失常药物(6 例中的 3 例)、地高辛(6 例中的 2 例)和胺碘酮(6 例中的 1 例)有关。在 6 例患者中发现了心电图有新的致心律失常迹象,但无新的心律失常需要停止治疗。结论:尽管罕见,新生儿和婴儿的非术后室上性心动过速可能是一种严重的疾病。控制心动过速的急性静脉内药物治疗可能会导致致命或近乎致命的后果。在新生儿中检测到与 IC 类抗心律失常药物相关的致心律失常可能特别困难,需要提高警惕。已知:儿童室上性心动过速的预后被认为是极好的,致命结果很少见。在非常年幼的儿童和有结构性心脏病的儿童中,死亡率增加。新发现:非术后室上性心动过速复杂的结果与较低的体重、年龄、产前心动过速、较高的 PRISM II 评分、控制心动过速的时间较长和致心律失常有关。在新生儿中检测到 IC 类致心律失常作用特别困难,因为他们的 QRS 较窄,因此需要提高警惕。